Latest Vaxcyte News & Updates

See the latest news and media coverage for Vaxcyte. We track all announcements, press releases, and industry mentions in real time, all in one place.

Vaxcyte

Clinical-stage vaccine biotechnology company

vaxcyte.com

Headquarters: San Carlos, United States
Founded year: 2013
Company type: Public company
Number of employees: 500–1,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Vaxcyte

In short: Vaxcyte launched up to $1.5 billion in offerings and reported positive OPUS-1 Phase 3 topline results for its VAX-31 pneumococcal vaccine.

Company announcements

Yesterday Vaxcyte

Vaxcyte files prospectus for common stock offering

Filed October 5, 2026, the registration supports a concurrent convertible note offering and follows positive OPUS-1 trial results.

Yesterday Vaxcyte

Vaxcyte announces sale of shares by officer Cowan Elvia

Elvia sells 1,900,016.48 common shares via UBS on October 5, 2026, acquired through stock option exercises for $10 million.

Yesterday Vaxcyte

Vaxcyte files Form 8-K with the SEC on October 5, 2026

The filing reports unscheduled material events or corporate events. It serves as a current report to investors regarding specific company developments.

October 4 Vaxcyte

Vaxcyte hosts call for OPUS-1 trial data

The event presents topline results from the Phase 3 trial of VAX-31 vaccine on October 5. Participation details include a dial-in number and webcast link.

Media coverage

Today Yahoo Finance

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.

Yesterday Yahoo Finance

Vaxcyte Stock Hits New 52-Week High - Here’s Why

Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an...

Yesterday Financial Times

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded...

January 23 Benzinga

Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase

Vaxcyte, Inc. (NASDAQ: PCVX), with a market capitalization of around $7 billion, is trading higher on Friday. The stock's positive movement comes as Vaxcyte is...

Never miss news about Vaxcyte

Track Vaxcyte and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Vaxcyte competitors & trending companies

Browse news for competitors to Vaxcyte and other trending companies.